Background Surveillance data indicate a decline in the prevalence of antiretroviral drug resistance among treated patients. Improved treatment strategies.

Slides:

Advertisements

Similar presentations

M ANAGING ARV REGIMEN FAILURE IN THE HIV INFECTED CHILD Dr L Keet Centre of Excellence HIV Directorate.

Advertisements

CHER Trial: Early Antiretroviral Therapy and Mortality Among HIV- Infected Infants New England J Med 2008;359 (21):

High rates of survival, virologic suppression and immune reconstitution among patients receiving second-line ART in the Indian national programme B.B.

Affordable Resistance Testing for Africa (ART-A)

HIV in the United Kingdom: 2013 HIV and AIDS Reporting Section Centre for Infectious Disease Surveillance and Control (CIDSC) Public Health England London,

Changing Therapy Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents published October 2006 AETC NRC Slide Set.

Alternative antiretroviral monitoring strategies for HIV-infected patients in resource-limited settings: Opportunities to save more lives? R Scott Braithwaite,

6/28/00TPED1 Resistance Testing: What is it? What does it mean? How does drug resistance emerge? Overview of methods Advantages and disadvantages Current.

Cost-effectiveness of different starting criteria of antiretroviral therapy in Mexico. Caro Y., Colchero A., Valencia A., Bautista-Arredondo S., Sierra.

The UNITAID-funded MSF diagnostics project: Plans to incorporate the new WHO recommendations and how best practices will be shared with, and disseminated.

Persisting long term benefit of genotypic guided treatment in HIV infected patients failing HAART and Importance of Protease Inhibitor plasma levels. Viradapt.

Summary Slide Presentation Primary drug resistance in South Africa - data from 10 years of surveys Manasa J, Katzenstein D, Cassol S, Newell ML, de Oliveira.

Characteristics and Outcomes of a Population of Tuberculosis Inpatients in Lilongwe, Malawi Mina Hosseinipour, MD, MPH Clinical Director UNC Project Lilongwe,

Presentation Title Presenter(s) Centers for Disease Control and Prevention AIDS Turning the Tide Together.

1 Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.

THE NEVEREST STUDY AT RAHIMA MOOSA MCH Ashraf Coovadia Adjunct Professor Enhancing Childhood HIV Outcomes (Wits Paediatric HIV Clinics) Rahima Moosa Mother.

Global HIV Resistance: The Implications of Transmission

HEPATITIS C VIRUS REINFECTION IN PEOPLE WHO INJECT DRUG (PWID) PREVIOUSLY SUCCESFULY TREATED G. Ntetskas, V. Papastergiou, L. Skorda, A. Katsili, E. Anastasiou,

Summary Slide Presentation Are subtype differences important in HIV drug resistance? Lessells RJ, Katzenstein DK, de Oliveira T. Are subtype differences.

HIV-1 Resistance - Implications For Clinicians Joseph J. Eron Jr., MD Professor of Medicine University of North Carolina.

BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.

PREVALENCE OF MDR-TB AMONGST PATIENTS WITH HIV AND TB CO- INFECTION SEEN AT THE DOTS CLINIC OF N.I.M.R., LAGOS, NIGERIA. Enya V.N.V, Onubogu C.C., Wahab.

The Positive Predictive Value of World Health Organization (WHO) Immunologic Criteria for Treatment Failure in a Public Health Antiretroviral Delivery.

The Use of Pooled Viral Load Testing to Identify Antiretroviral Treatment Failure Davey Smith 1, Susanne May 2, Josué Perez-Santiago 1, Matthew Strain.

The WHO HIV Drug Resistance Strategy Presented by Dr. Don Sutherland Prepared by: Dr. Don Sutherland Dr Silvia Bertagnolio Dr Diane Bennett HIV Drug Resistance.

Detection of clinically relevant antiretroviral drug resistance mutations among treated patients undergoing testing at low levels of viremia AM Geretti.

ZIMBABWE AIDS CARE FOUNDATION NEWLANDS CLINIC Virological Outcomes in Adult Patients on Second Line ART, at Newlands Clinic Dr S. Bote.

Unit 6: Specialised Techniques: Anti-Microbial Resistance Monitoring and Assessment of STI Syndrome Aetiologies #4-6-1.

ANTEPARTUM CARE. Pregnant Women Who Are ARV Naive (1)  Pregnant women with HIV infection should receive standard clinical, immunologic, and virologic.

Transmitted drug resistance Pat Cane. Questions What is the level of TDR and is it changing? Are we measuring TDR accurately? Are more sensitive methods.

National Prevalence of Transmitted HIV Drug Resistance in Swaziland in 2011 R. Suzanne Beard, Ph.D. Abstract/poster: TUPDC0103.

HIV-1 Resistance - Implications For Clinicians Joseph J. Eron Jr., MD Professor of Medicine University of North Carolina.

Washington D.C., USA, July 2012www.aids2012.org Changing Patterns of NRTI and PI Resistance Mutations Between 2006 and 2011 in ART experienced SA.

THE 6 TH NATIONAL SCIENTIFIC CONFERENCE ON HIV/AIDS Evaluation of two techniques for viral load monitoring on DBS ANRS project Phase I - Laboratory.

Strategies for Management of Antiretroviral Therapy Study Wafaa El-Sadr and James Neaton for the SMART Study Team.

Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.

Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Low-Frequency HIV-1 Drug Resistance Mutations and.

Serologic markers and molecular epidemiology of HBV from an HIV infected cohort from Cameroon Tshifhiwa Magoro 1, Emmaculate Nongpang 2, Lufuno Mavhandu.

Response to Antiretroviral Treatment In an Ethiopian Hospital Samuel Hailemariam, MD, MPH; J Allen McCutchan, MD, MSc Meaza Demissie, MD, PMH, PHD; Alemayehu.

Meeting the Global Challenge ~ International workshop on antiviral drug resistance.

2 3 Population : 6,934,169 inhabitants 6 Sanitary regions UNAIDS (2014) - HIV prevalence : 2.5% = 110,000 PLHIV - Higher prevalence in southern regions.

HIV Drug Resistance Surveillance Satellite Session: HIV Drug Resistance Surveillance and Control: a Global Concern Silvia Bertagnolio, MD WHO,

Hepatitis B virus infection in renal transplant recipients

High prevalence of antiretroviral drug resistance among HIV-infected pregnant women in Buenos Aires, Argentina Zapiola 1, D.M. Cecchini 2, S. Fernandez.

Interim Analysis of a 3-Year Follow-up Study of NS5A and NS3 Resistance-Associated Variants After Treatment With Grazoprevir-Containing Regimens in Patients.

PRESENTED AT THE 9TH IAS CONFERENCE ON HIV SCIENCE - PARIS, FRANCE

Learning objectives Define HIV treatment goals

MOVING FORWARD Enhanced ART Monitoring in Countries: Botswana

Acceptability of early HIV treatment among South Africa women N Garrett, E Norman, V Asari, N Naicker, N Majola, K Leask, Q Abdool Karim and SS Abdool.

Alarming rates of virological failure and drug resistance in patients on long-term antiretroviral treatment in routine HIV clinics in Togo. Abla A. KONOU,

A qualitative PCR minipool strategy to screen for virologic failure and antiretroviral drug resistance in South African patients on first-line antiretroviral.

INPUT OF PMTCT TO ZERO NEW HIV INFECTION-CAMPAIGN IN RWANDA: Case of MUHIMA District Hospital By NTACYABUKURA Blaise, University of Rwanda, college of.

Figure 1 Inclusion criteria, exclusion criteria, and criteria for virologic failure. CDC, Centers for Disease Control and Prevention; ddC, zalcitabine;

Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort.

Background Results Methods Conclusion

Validating Definitions of Antiretroviral Treatment Failure in Malawi

Dolutegravir versus Raltegravir in Treatment Experienced SAILING Study

Resistance to HCV direct-acting antivirals: What should we know?

Utilizing research as an opportunity to strengthen

RESISTANT HYPERTENSION OR POOR PATIENT ADHERENCE? TIPS TO GAIN CONTROL

Starting Strong: Initial Evaluation of the Patient With HCV

St Stephen’s Centre, Chelsea & Westminster Hospital, United Kingdom

Advancing the Treatment of IBD With Biologics

Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes:

Drug-resistant human immunodefiency virus

Background. Long-Term B/F/TAF Switch Efficacy in Patients with Archived Pre-Existing Resistance.

Update on global progress in ART

Rapid Detection of HIV-1 subtype C Integrase resistance mutations by the Use of High-Resolution Melting Analysis Tendai Washaya BSc, Msc. Pre-PhD Student.

HVDRS STUDY RESISTANCE: WE CARE

Share your thoughts on this presentation with #IAS2019

Presentation transcript:

Background Surveillance data indicate a decline in the prevalence of antiretroviral drug resistance among treated patients. Improved treatment strategies and prompt detection and management of virological failure may contribute to reduce the emergence of resistance. A VL >1000 cp/ml is the recommended optimal threshold for resistance testing. Genotypic resistance assays however can be adapted to perform well at low VL, although some debate ensues as to whether results are fully representative of the dominant quasispecies. Resistance testing at low VL is often required in clinical practice to allow a timely and optimised therapeutic change, and many centres perform resistance tests at VL <1000 cp/ml as part of routine care 1,2. Yet, the yield and clinical utility of testing at low VL remain uncertain. Aims: To characterise the population undergoing genotypic resistance testing at VL <1000 cp/ml, describe their genotypic resistance profiles, and identify factors associated with the detection of resistance mutations among treated patients. Methods Resistance results from the UK HIV Drug Resistance Database were linked to clinical data from UK CHIC. The analysis considered all resistance tests performed after the start of HAART, with a matching VL measured within the previous 4 wks. For patients with multiple tests, all results were included. Major resistance mutations were scored by the IAS-USA list (Sept-Oct 2007). Virological failure of a drug was defined by VL >400 cp/ml after >4 months of continuous use of the drug. Sequencing success rate in centres providing specialised testing at VL <1000 cp/ml was 85%. Generalized linear models with log link and Poisson error (using GEE) were used to assess multivariable (adjusted) relative risks (SAS 9.1). Prevalence and Patterns of Antiretroviral Drug Resistance at Low Plasma HIV RNA Load Levels Geretti AM 1, Phillips A 1, Kaye S 2, Booth C 1, Garcia A 1, Mackie N 2, on behalf of the UK HIV Drug Resistance Database and CHIC Study. 1 Royal Free & University College Medical School, 2 Imperial College Healthcare NHS Trust, London, UK Cohort (%)High-VL (%)Low-VL (%)P* GenderMale6199 (78.7)5444 (79.2)755 (75.4) Female1679 (21.3)1433 (20.8)246 (24.6) Age< (8.5) 604 (8.8) 67 (6.7) (68.9)4764 (69.3)661 (66.0) > (22.6)1510 (22.0)273 (27.3) HIV exposure MSM4771 (60.6)4200 (61.1)571 (57.0) Hetero2275 (28.9)1956 (28.4)319 (31.9) IDU 355 (4.5) 321 (4.7) 34 (3.4) Other/Unk 478 (6.1) 401 (5.8) 77 (7.7) Current regimen NNRTI + NRTIs1856 (23.6)1572 (22.9)284 (28.4)< PI/r + NRTIs1798 (22.8)1469 (21.4)329 (32.9) PI + NRTIs 950 (12.1) 850 (12.4)100 (10.0) NRTIs only1124 (14.3) 967 (14.1)157 (15.7) Other 539 (6.8) 481 (7.0) 58 (5.8) Off treatment1612 (20.5)1539 (22.4) 73 (7.3) Number of drugs previously failed (12.9) 831 (12.1)183 (18.3)< (31.9)2244 (32.6)273 (27.3) (31.4)2166 (31.5)305 (30.5) (17.5)1194 (17.4)183 (18.3) > (6.3) 443 (6.4) 57 (5.7) Time since start of HAART 0-3 years2792 (35.4)2462 (35.8)330 (33.0)< years2407 (30.5)2123 (30.9)284 (28.4) 6-9 years1621 (20.6)1416 (20.6)205 (20.5) > 9 years1059 (13.4) 877 (12.7)182 (18.2) VL ever <50 cp/ml Yes4499 (57.1)3733 (54.3)766 (76.5)< No3380 (42.9)3145 (45.7)235 (23.5) Table 1. Cohort undergoing resistance testing Prevalence (%) of resistance Proportion (%) of total tests Whole cohortNN (%) with RAMsRR (95% CI) < (60)0.94 ( ) (72)0.99 ( ) (76) (77)1.01 ( ) (67)0.91 ( ) (60)0.84 ( ) (49)0.70 ( ) NRTIsNN (%) with NAMsRR (95% CI) < (53)0.89 ( ) (68)1.00 ( ) (72) (75)1.01 ( ) (70)0.93 ( ) (59)0.79 ( ) (45)0.62 ( ) NRTIs+NNRTINN (%) with nNAMsRR (95% CI) < (48)0.86 ( ) (77)1.06 ( ) (77) (77)1.02 ( ) (73)0.97 ( ) (60)0.84 ( ) (48)0.68 ( ) NRTIs+PI*NN (%) with PRAMsRR (95% CI) < (29)0.85 ( ) (38)1.00 ( ) (43) (46)0.89 ( ) 10, (44)0.88 ( ) 30, (41)0.85 ( ) 100, (31)0.66 ( ) Table 3. Multivariate relative risk (RR) of detecting resistance according to the VL in the whole cohort, and while on NRTIs, NRTIs+NNRTI, or NRTIs+PI* *chi-square test Conclusions Testing at VL <1000 cp/ml is as likely to detect resistance as testing at higher levels. The yield of testing declines progressively at VL cp/ml for NAMs and for nNAMS and PRAMs. Common (>5%) mutations at VL<1000 cp/ml include the NAMs K65R, M184V, and TAMs, the nNAMs K103N, Y181C and G190A, and the PRAMs M46I, V82A, and L90M. Testing at low-VL does not explain the observed decline in the prevalence of antiretroviral drug resistance among treated patients. The findings rather indicate a protective role of newer treatment regimens and use of PI/r. *Includes both PI and PI/r RR (95% CI)P Calendar yr of testPer yr more recent 0.96( )< Current regimenNNRTI+NRTIs1.00-< NRTIs+PI0.91( ) NRTIs+PI/r 0.73( ) NRTIs0.95( ) Other0.90( ) Off0.54( ) Number of drugs previously failed 00.50( ) ( ) ( ) ( ) > < Time since start of HAARTPer yr greater VL ever <50 cp/mlYes0.90( ) No1.00-< Table 2. Independent predictors of resistance Results The dataset comprised 7879 resistance test results, from 3795 patients with 1 test, 1817 with 2 tests and 2267 with 3 tests. Most patients were receiving HAART with 2 NRTIs plus either NNRTI or PI/r. There were 1621 tests done off treatment, after patients had discontinued HAART for median 542 days (IQR ) (Table 1). 1001/7879 (12.7%) tests were performed at VL 1000 cp/ml (high-VL). The total number of tests remained fairly stable through the years, while the proportion at low- VL increased significantly, from 3.4% before 1999 to 21.8% in 2006 (chi- square test, p<0.0001) (Fig 1). In the whole cohort, the overall prevalence of major resistance- associated mutations (RAMs) declined over time (Fig 2). Factors independently associated with the detection of resistance in the multivariate analysis are indicated in Table 2. There was no significant effect of gender, age, risk group, and only a marginal effect of time since start of HAART. In the multivariate analysis, the relative risk (RR) of detecting any resistance was highest at VL 1000 and <10000 cp/ml and overall similar at VL<1000 cp/ml (Table 3). The frequency of RT and PR mutations in the whole cohort, stratified by VL, is shown in Fig 3. Among low-VL patients on PIs at the time of testing, mutations detected at a frequency 5% included D30N (5%), M46I (10%), V82A (11%), I84V (5%) and L90M (14%) (not shown). Fig 3. Frequency of RT and PR mutations % NRTIs+PI/rNN (%) with PRAMsRR (95% CI) < (24)0.84 ( ) (30)0.98 ( ) (37) (40)0.94 ( ) (38)0.93 ( ) (37)0.83 ( ) (27)0.70 ( ) References: 1. Mackie et al, J Virol Methods 2004; 2. Cane et al, HIV Med 2008 RAMS: Resistance-associated mutations; NAMs: NRTI RAMs; nNAMs: NNRTI RAMs; PRAMs: PI RAMs.